Top Markets
#1 Helium Helium +59.21%
#2 GEKKO GEKKO +52.86%
#3 TENDIES TENDIES +41.58%
#4 ADO Protocol ADO Protocol +39.01%
#5 Pons Pons +33.75%
#6 StonkBroker StonkBroker +31.45%
#7 Collector Crypt Collector Crypt +28.71%
#8 Prom Prom +28.68%
#9 o1.exchange o1.exchange +22.50%
#10 龙虾 (Lobster) 龙虾 (Lobster) +19.60%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Jiangsu Yahong Meditech Co Ltd Jiangsu Yahong Meditech Co Ltd

Jiangsu Yahong Meditech Co Ltd

688176
Classement en actions #9583
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong... Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
Prix de l'action
$1.72
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$985.07M
Changement (1 jour)
-0.50%
Changement (1 an)
6.01%
Pays
CN
Échange Jiangsu Yahong Meditech Co Ltd (688176)

Catégorie

Healthcare
EPS pour Jiangsu Yahong Meditech Co Ltd (688176)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Jiangsu Yahong Meditech Co Ltd, l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Jiangsu Yahong Meditech Co Ltd de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $0.56 -
IN